# PHAT catalysts: Phathom Pharmaceuticals, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/phat/catalysts

> Phathom Pharmaceuticals, Inc. (PHAT) has 4 upcoming catalysts. The next is the VOQUEZNA® (vonoprazan) topline data readout, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for PHAT?

Phathom Pharmaceuticals, Inc. (PHAT) has 4 upcoming catalysts. The next is the VOQUEZNA® (vonoprazan) topline data readout, 2027. Press release filed with the SEC (EX-99): "Topline results are anticipated in 2027." [Calendar and source filings](https://sec-api.dev/companies/phat/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-073377, https://www.sec.gov/Archives/edgar/data/1783183/000119312526073377/d119012dex991.htm (retrieved 2026-11-12). Last confirmed 2026-02-26. Cite: https://sec-api.dev/companies/phat/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Phathom Pharmaceuticals, Inc. |
| Ticker | PHAT (Nasdaq) |
| SEC CIK | 1783183 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/phat |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 3, 2022 | [Voquezna Triple Pak (amoxicillin; clarithromycin; vonoprazan fumarate) FDA approval](https://sec-api.dev/pdufa/amoxicillin-clarithromycin-vonoprazan) | PHAT |  | completed, approved | "NDA215152 ORIG-1 (Type 1 - New Molecular Entity and Type 4 - New Combination): submission_status AP, submission_status_date 20220503, review_priority PRIORITY; sponsor_name PHATHOM; product VOQUEZNA TRIPLE PAK (AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215152%22)) |
| May 3, 2022 | [Voquezna Dual Pak (amoxicillin; vonoprazan fumarate) FDA approval](https://sec-api.dev/pdufa/amoxicillin-vonoprazan) | PHAT |  | completed, approved | "NDA215153 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20220503, review_priority PRIORITY; sponsor_name PHATHOM; product VOQUEZNA DUAL PAK (AMOXICILLIN; VONOPRAZAN FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215153%22)) |
| Jan 2023 | [NERD-301 topline data readout](https://sec-api.dev/pdufa/nerd-301) | PHAT | Non-Erosive reflux disease, or Non-Erosive GERD | completed, positive | "In January 2023, we reported positive topline data from the primary endpoint in PHALCON-NERD-301, our Phase 3 study evaluating the safety and efficacy of vonoprazan 10 mg and 20 mg as a daily dosing (QD) treatment, as compared to placebo (QD), in the relief of heartburn over four weeks in adult participants with Non-Erosive reflux disease, or Non-Erosive GERD." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1783183/000095017025034183/phat-20241231.htm)) |
| February 7, 2023 | [VOQUEZNA® (vonoprazan) complete response letter (CRL)](https://sec-api.dev/pdufa/vonoprazan) | PHAT |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22215151_2024_Orig1s000OtherActionLtrs.pdf%22)) |
| Sep 2023 | [VOQUEZNA® (vonoprazan) NDA/BLA submission](https://sec-api.dev/pdufa/vonoprazan) | PHAT |  | completed | "In September 2023, we submitted an NDA seeking approval of vonoprazan as a once-daily treatment for heartburn symptoms associated with Non-Erosive GERD in adults." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1783183/000119312525257390/phat-20250930.htm)) |
| Nov 2023 | [VOQUEZNA® (vonoprazan) NDA/BLA submission](https://sec-api.dev/pdufa/vonoprazan) | PHAT |  | completed | "In November 2023, we received FDA approval of vonoprazan, under the brand name VOQUEZNA, for the healing and maintenance of healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults, and in September 2023, we submitted an NDA seeking approval of vonoprazan as a once-daily treatment of heartburn associated with Non-Erosive GERD in adults." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1783183/000095017025034183/phat-20241231.htm)) |
| November 1, 2023 | [VOQUEZNA® (vonoprazan) FDA approval](https://sec-api.dev/pdufa/vonoprazan) | PHAT | erosive gastroesophageal reflux disease, or Erosive GERD | completed, approved | "On November 1, 2023, the FDA approved the Company's NDA for VOQUEZNA 10 mg and 20 mg tablets for the treatment of erosive gastroesophageal reflux disease, or Erosive GERD." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1783183/000119312526436961/phat-20260930.htm)) |
| July 17, 2024 | [VOQUEZNA® (vonoprazan) FDA approval](https://sec-api.dev/pdufa/vonoprazan) | PHAT |  | completed, approved | "The royalty rate is subject to a step-down on net sales exceeding certain annual thresholds and when the Company received FDA approval for vonoprazan for an indication relating to the treatment of heartburn associated with Non-Erosive GERD, which occurred on July 17, 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1783183/000119312526436961/phat-20260930.htm)) |
| 2025 | [Amoxicillin trial start](https://sec-api.dev/pdufa/amoxicillin) | PHAT | severe Erosive GERD in 2025 and two H | scheduled | "In the U.S., Cinclus obtained FDA agreement on their linaprazan glurate pediatric plan and plans to initiate two linaprazan glurate Phase 3 studies in patients with severe Erosive GERD in 2025 and two H. pylori Phase 3 dual therapy (with amoxicillin) studies in 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1783183/000095017025034183/phat-20241231.htm)) |
| March 6, 2025 | [Phathom Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/phat/catalysts) | PHAT |  | completed | "Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783183/000119312525047882/d940367dex991.htm)) |
| May 1, 2025 | [Phathom Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/phat/catalysts) | PHAT |  | completed | "Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783183/000119312525108726/d847727dex991.htm)) |
| June 6, 2025 | [VOQUEZNA® (vonoprazan) FDA approval](https://sec-api.dev/pdufa/vonoprazan) | PHAT |  | completed, approved | "As referenced above, on June 6, 2025, the FDA has approved the Citizen Petition and communicated its intention to correct the Orange Book to recognize the proper 10 years of New Chemical Entity exclusivity for VOQUEZNA® (vonoprazan) tablets, extending through May 3, 2032." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1783183/000119312525137094/d941196d8k.htm)) |
| August 7, 2025 | [Phathom Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/phat/catalysts) | PHAT |  | completed | "Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783183/000119312525174943/d907916dex991.htm)) |
| Q4 2025 | [VOQUEZNA® (vonoprazan) trial start](https://sec-api.dev/pdufa/vonoprazan) | PHAT |  | scheduled | "We plan to initiate our Phase 2 clinical trial of vonoprazan in eosinophilic esophagitis (EoE) trial during the fourth quarter of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1783183/000095017025104548/phat-20250630.htm)) |
| October 30, 2025 | [Phathom Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/phat/catalysts) | PHAT |  | completed | "Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783183/000119312525257382/d68071dex991.htm)) |
| November 4, 2025 | [VOQUEZNA® (vonoprazan) trial start](https://sec-api.dev/pdufa/vonoprazan) | PHAT |  | completed | "On November 4, 2025, Phathom Pharmaceuticals, Inc. ("Phathom" or the "Company") announced the first patient has been dosed in its Phase 2 pHalcon EoE-201 clinical trial evaluating VOQUEZNA® (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis ("EoE") in adults." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1783183/000119312525263534/d20656d8k.htm)) |
| January 7, 2026 | [Phathom Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/phat/catalysts) | PHAT |  | completed | "Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783183/000119312526006266/d52798dex991.htm)) |
| February 26, 2026 | [Phathom Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/phat/catalysts) | PHAT |  | completed | "Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783183/000119312526073377/d119012dex991.htm)) |
| April 30, 2026 | [Phathom Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/phat/catalysts) | PHAT |  | completed | "Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783183/000119312526193945/d140332dex991.htm)) |
| July 30, 2026 | [Phathom Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/phat/catalysts) | PHAT |  | completed | "Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783183/000119312526324865/d114879dex991.htm)) |
| September 11, 2026 | [VOQUEZNA® (vonoprazan) primary completion](https://sec-api.dev/pdufa/vonoprazan) | PHAT | Eosinophilic Esophagitis | completed | "NCT06851559 (A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-11 (ACTUAL); Lead Sponsor Phathom Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06851559)) |
| Q4 2026 | [VOQUEZNA® (vonoprazan) topline data readout](https://sec-api.dev/pdufa/vonoprazan) | PHAT | eosinophilic esophagitis | scheduled | "Topline results are anticipated in the fourth quarter 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1783183/000119312526278533/d166684d8k.htm)) |
| October 29, 2026 | [Phathom Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/phat/catalysts) | PHAT |  | completed | "Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783183/000119312526436959/d180192dex991.htm)) |
| 2027 | [VOQUEZNA® (vonoprazan) topline data readout](https://sec-api.dev/pdufa/vonoprazan) | PHAT |  | scheduled | "Topline results are anticipated in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783183/000119312526073377/d119012dex991.htm)) |
| October 2027 | [VOQUEZNA® (vonoprazan) primary completion](https://sec-api.dev/pdufa/vonoprazan) | PHAT | Symptomatic Non-erosive Gastroesophageal Reflux Disease | scheduled | "NCT07752407 (A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-20 (ESTIMATED); Lead Sponsor Phathom Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07752407)) |
| Q1 2028 | [NERD-302 topline data readout](https://sec-api.dev/pdufa/nerd-302) | PHAT |  | scheduled | "Topline results are expected in the first quarter of 2028." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1783183/000119312526407696/d22070d8k.htm)) |
| Q1 2028 | [VOQUEZNA® (vonoprazan) topline data readout](https://sec-api.dev/pdufa/vonoprazan) | PHAT | Symptomatic Non-erosive Gastroesophageal Reflux Disease | scheduled | "The first subject has been dosed, and sites are currently enrolling across the U.S. Topline results are expected in the first quarter 2028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783183/000119312526436959/d180192dex991.htm)) |

## Drugs

- [Amoxicillin](https://sec-api.dev/pdufa/amoxicillin): severe erosive gerd in 2025 and two h
- [Voquezna Triple Pak (amoxicillin; clarithromycin; vonoprazan fumarate)](https://sec-api.dev/pdufa/amoxicillin-clarithromycin-vonoprazan): 
- [Voquezna Dual Pak (amoxicillin; vonoprazan fumarate)](https://sec-api.dev/pdufa/amoxicillin-vonoprazan): 
- [NERD-301](https://sec-api.dev/pdufa/nerd-301): non-erosive reflux disease, or non-erosive gerd
- [NERD-302](https://sec-api.dev/pdufa/nerd-302): 
- [VOQUEZNA® (vonoprazan)](https://sec-api.dev/pdufa/vonoprazan): erosive gastroesophageal reflux disease, or erosive gerd, eosinophilic esophagitis, Symptomatic Non-erosive Gastroesophageal Reflux Disease

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/phat/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PHAT catalysts: Phathom Pharmaceuticals, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/phat/catalysts

```bibtex
@misc{secapidev_companies_phat_catalysts_20261116,
  title        = {PHAT catalysts: Phathom Pharmaceuticals, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/phat/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_phat_catalysts_20261116","title":"PHAT catalysts: Phathom Pharmaceuticals, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/phat/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
